AbClon Inc Net Assets
AbClon Inc net assets. Based on the latest financial reports, AbClon Inc (174900) has net assets worth ₩53.07 Billion KRW (≈ $35.97 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩64.50 Billion ≈ $43.71 Million USD) and total liabilities (₩11.43 Billion ≈ $7.75 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore AbClon Inc equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩53.07 Billion |
| % of Total Assets | 82.28% |
| Annual Growth Rate | 16.34% |
| 5-Year Change | 212.2% |
| 10-Year Change | 404.54% |
| Growth Volatility | 49.75 |
Net Assets of AbClon Inc (2015–2025)
Net assets of AbClon Inc from 2015 to 2025. This chart illustrates how AbClon Inc's net assets have evolved over time, based on quarterly financial data. See 174900 net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for AbClon Inc (2015–2025)
The table below shows the annual net assets of AbClon Inc from 2015 to 2025. For live market cap and overall valuation, see AbClon Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩60.44 Billion ≈ $40.96 Million |
+105.53% |
| 2024-12-31 | ₩29.41 Billion ≈ $19.93 Million |
+7.98% |
| 2023-12-31 | ₩27.23 Billion ≈ $18.46 Million |
-25.60% |
| 2022-12-31 | ₩36.60 Billion ≈ $24.81 Million |
+89.08% |
| 2021-12-31 | ₩19.36 Billion ≈ $13.12 Million |
-33.99% |
| 2020-12-31 | ₩29.33 Billion ≈ $19.88 Million |
-17.10% |
| 2019-12-31 | ₩35.38 Billion ≈ $23.98 Million |
+89.20% |
| 2018-12-31 | ₩18.70 Billion ≈ $12.67 Million |
+7.51% |
| 2017-12-31 | ₩17.39 Billion ≈ $11.79 Million |
+45.19% |
| 2016-12-31 | ₩11.98 Billion ≈ $8.12 Million |
-9.98% |
| 2015-12-31 | ₩13.31 Billion ≈ $9.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to AbClon Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7451681418000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
AbClon Inc Net Assets Breakdown (December 2025)
AbClon Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩151.23 Billion | 250.22% |
| Total Equity | ₩60.44 Billion | 100.00% |
AbClon Inc Competitors by Market Cap
The table below lists competitors of AbClon Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Joyvio Agriculture Development Co Ltd
SHE:300268
|
$240.63 Million |
|
P.C.B Tec
TA:PCBT
|
$240.65 Million |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
$240.75 Million |
|
Suprema Inc
KQ:236200
|
$240.78 Million |
|
Vimta Labs Limited
NSE:VIMTALABS
|
$240.60 Million |
|
Silver Storm Mining Ltd.
V:SVRS
|
$240.51 Million |
|
Profit Cultural & Creative Group Co Ltd
SHE:300640
|
$240.28 Million |
|
Texas Ventures Acquisition III Corp
NASDAQ:TVA
|
$240.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AbClon Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 29,405,991,610 to 60,438,725,800, a change of 31,032,734,190 (105.5%).
- Net loss of 17,906,959,740 reduced equity.
- New share issuances of 22,952,021,380 increased equity.
- Other factors increased equity by 25,987,672,550.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-17.91 Billion | -29.63% |
| Share Issuances | ₩22.95 Billion | +37.98% |
| Other Changes | ₩25.99 Billion | +43.0% |
| Total Change | ₩- | 105.53% |
Book Value vs Market Value Analysis
This analysis compares AbClon Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 18.15x to 5.87x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩982.08 | ₩17820.00 | x |
| 2017-12-31 | ₩1278.84 | ₩17820.00 | x |
| 2018-12-31 | ₩1305.79 | ₩17820.00 | x |
| 2019-12-31 | ₩2465.05 | ₩17820.00 | x |
| 2020-12-31 | ₩1919.69 | ₩17820.00 | x |
| 2021-12-31 | ₩1267.10 | ₩17820.00 | x |
| 2022-12-31 | ₩2389.56 | ₩17820.00 | x |
| 2023-12-31 | ₩1753.50 | ₩17820.00 | x |
| 2024-12-31 | ₩1687.56 | ₩17820.00 | x |
| 2025-12-31 | ₩3033.23 | ₩17820.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AbClon Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -379.86%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.17x
- Recent ROE (-29.63%) is below the historical average (-29.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -73.96% | -505.24% | 0.12x | 1.21x | ₩-11.17 Billion |
| 2016 | -13.33% | -51.17% | 0.19x | 1.34x | ₩-2.79 Billion |
| 2017 | -8.52% | -41.97% | 0.17x | 1.20x | ₩-3.22 Billion |
| 2018 | -4.51% | -21.49% | 0.14x | 1.54x | ₩-2.71 Billion |
| 2019 | 7.25% | 17.85% | 0.31x | 1.33x | ₩-971.27 Million |
| 2020 | -21.97% | -232.57% | 0.07x | 1.37x | ₩-9.38 Billion |
| 2021 | -52.88% | -339.22% | 0.10x | 1.54x | ₩-12.17 Billion |
| 2022 | -25.28% | -271.66% | 0.06x | 1.48x | ₩-12.91 Billion |
| 2023 | -47.39% | -448.53% | 0.06x | 1.67x | ₩-15.63 Billion |
| 2024 | -55.44% | -696.70% | 0.05x | 1.64x | ₩-19.24 Billion |
| 2025 | -29.63% | -379.86% | 0.07x | 1.17x | ₩-23.95 Billion |
Industry Comparison
This section compares AbClon Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $417,529,273,243
- Average return on equity (ROE) among peers: -6.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AbClon Inc (174900) | ₩53.07 Billion | -73.96% | 0.22x | $240.63 Million |
| ORIENTBIO Inc. (002630) | $97.94 Billion | -19.53% | 0.76x | $96.19 Million |
| Green Cross (005250) | $1.97 Trillion | 1.67% | 0.83x | $290.81 Million |
| Green Cross Holdings Preference Shares (005257) | $1.67 Trillion | 10.22% | 0.94x | $2.85 Million |
| Pharmicell (005690) | $86.44 Billion | 7.32% | 0.15x | $367.60 Million |
| GeneOne Life Science Inc (011000) | $111.49 Billion | -69.75% | 0.35x | $32.81 Million |
| HLB Co. Ltd (028300) | $88.75 Billion | -14.89% | 1.10x | $3.02 Billion |
| Mgenplus Co. Ltd. (032790) | $18.79 Billion | 0.00% | 1.65x | $19.98 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $13.93 Million |
| Seoulin Bioscience Co.Ltd (038070) | $45.30 Billion | 4.03% | 0.46x | $21.44 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $356.42 Million |
About AbClon Inc
AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is… Read more